Amendments to the Claims

Please amend claims 1, 4, 5, and 95

Please cancel claims 6 and 99.

1. (currently amended) A method for the treatment of autosomal recessive retinitis pigmentosa or congenital stationary night blindness ~~a disorder of the eye~~ comprising:

administering to a subject a therapeutically effective amount of a composition comprising a dsRNA between 21 and 23 nucleotides in length and a carrier, said dsRNA having a nucleotide sequence corresponding to mRNA of a target gene expressed in the eye; said administering of the composition occurring outside the blood-retina barrier, and said composition inhibiting the target gene by RNA interference inside the eye.

2-3. (canceled)

4. (currently amended) The method of claim 1, wherein said autosomal recessive retinitis pigmentosa or congenital stationary night blindness ~~disorder~~ is related to angiogenesis and/or neovascularization.

5. (currently amended) The method of claim 1, wherein said autosomal recessive retinitis pigmentosa or congenital stationary night blindness ~~disorder~~ is related to the retinal pigment epithelium (RPE), neurosensory retina, choroid, and a combination thereof.

6-15. (canceled)

16. (previously presented) The method of claim 1, wherein the dsRNA comprises a terminal 3'-hydroxyl group.

17.-93. (canceled)

94. (original) The method of claim 1, further comprising preparing the dsRNA.

95. (currently amended) The method of claim 1, further comprising diagnosing a subject with autosomal recessive retinitis pigmentosa or congenital stationary night blindness ~~a disorder~~ or a predisposition to autosomal recessive retinitis pigmentosa or congenital stationary night blindness ~~a disorder of the eye~~.

96. (canceled)

97. (original) The method of claim 1, further comprising isolating the target gene.

98. (previously presented) The method of claim 1, wherein said administering is by systemic administration.

99. (canceled)